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Abstract
Background: Hepatitis C virus (HCV) infections are a severe burden on public health worldwide, causing mortality
rates triple that of the general population. Since 2011, for both therapy-naive and therapy-experienced genotype 1
patients, the first generation of direct acting antivirals (DAAs), i.e., the protease-inhibitors (PI) telaprevir and boceprevir
have been added to existing dual therapies. The therapeutic effect of the resulting triple therapy is striking; however,
treatment regimens are complex and commonly cause side effects. Little is known of how patients implement therapy
in their daily lives, or of how they deal with these effects.
This study aims to describe HCV patients' experiences with protease-inhibitor-based triple therapy and their support
needs.
Methods: A qualitative design was used. Patients from three outpatient clinics, with ongoing, completed or
discontinued PI treatment experience were recruited using a maximum variation sampling approach.
Open-ended interviews were conducted and analyzed using thematic analysis according to Braun & Clarke
(Qual Res Psychol 3:77-101, 2006).
Results: Thirteen patients participated in the interviews. All described themselves as highly motivated to
undergo treatment, since they saw the new therapy as a “real chance” for a cure. However, all later described
the therapy period as a struggle. The constitutive theme–“Fighting an uphill battle”– describes the common
existential experience of and negative consequences of coping with side effects. The processes that fostered
this common experience followed three sub-themes: “encountering surprises”, “dealing with disruption” and
“reaching the limits of systems”.
Conclusion: HCV patients undergoing outpatient protease-inhibitor-based triple therapy need systematic support in
symptom management. This will require specially trained professionals to advise and support them and their families,
and to provide rapid responses to their needs throughout this complex course of therapy. As the generation of DAAs
for all genotypes, are expected to have less severe side effects, and many HCV patients require treatment, this
knowledge can improve treatment support tremendously, especially for patients who are quite difficult to
treat. Furthermore, these findings are helpful to illustrate development in HCV treatment.
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Background
Hepatitis C virus (HCV) infections are a severe burden
on public health worldwide. As the main causes of cir-
rhosis and cancer of the liver, they are the most frequent
indication for liver transplantation [1,2]. It is estimated
that more than 160 million people currently live with
chronic HCV, including about 15 million in the WHO
European region [3,4]. In the United States, the HCV-
related mortality rate is triple that of the general popula-
tion [5], surpassing that of HIV [6].
Antiviral therapies' sustained virological response (SVR),
indicating that the patient is cured, is defined as the
absence of target virus RNA 24 weeks after the end of
therapy [7]. For more than 10 years, the standard treat-
ment for all six human-occurring HCV genotypes has
been a combination of pegylated interferon (IFN) and
ribavirin (RBV) (dual therapy), with SVR rates of 40-50%
for genotype 1 (the most common genotype in the United
States and Europe) [1,8]. However, since 2011, the first-
generation direct acting antivirals (DAAs), i.e., the protease-
inhibitors (PI) telaprevir (TPV) and boceprevir (BOC),
have been used in both therapy-naive and therapy-
experienced genotype 1 patients. Adding one of these PIs
to dual therapy (IFN/RBV) produces a "triple therapy"
(IFN/RBV/PI), leading to SVR rates as high as 70% [8-10].
Treatment time of triple therapy is 24 – 48 weeks. TPV is
prescribed at treatment start, while BOC is preceded by a
4-week lead-in phase with IFN/RBV. For monoinfected
patients with an optimal virological response, treatment
time can be shortened.
HCV care is usually performed in outpatient clinics. This
presumes that patients who start treatment are capable of
taking oral medication linked to dietary requirements,
e.g., TPV along with 21 grams of fat, and self-administering
subcutaneous injections at least twice daily. With triple
therapy, in order to prevent resistance, the protease-
inhibitor must be taken punctually three times a day,
i.e., every 8 hours [11]. Moreover, some evidence sug-
gests that a high proportion (>80%) of patients can
achieve the same results regardless of whether they take
TPV twice or three times daily [12]. However it has
been documented that some patients who lack effect-
ive support systems, or whose medical, behavioral or
social problems complicate treatment, do not receive
access to treatment [13,14].
Side effects of anti-HCV dual therapy can include flu-like
symptoms, fatigue, depression, skin problems or changes in
blood counts [15]. Under triple therapy, additional serious
side effects may occur, such as pronounced anemia, diar-
rhea, dysgeusia, severe skin rash or anorectal events [16].
Side effects have shown to be a serious burden for patients
and can even be life –threatening [17,18].
The complexity of the treatment plan and dealing with
various symptoms of the disease and its treatment places
great self-management demands on the patient. By
definition, self-management encompasses the day-to-day
activities a chronically ill patient performs to minimize
the negative consequences of his or her condition. Such
actions vary based on the persons’ perceptions, experi-
ences and expertise, but share the focus of optimizing
health outcomes and improving overall wellness [19,20].
During the course of HCV, patients have to deal with nu-
merous self-management tasks, including: a) understand-
ing the facts about HCV; b) making lifestyle changes to
maximize liver health; c) coming to terms with their diag-
nosis, mortality and transmission probabilities d) dealing
with disclosure, discrimination and stigma; e) organizing
emotional support; f ) managing the disease alongside
work and family; and g) making ongoing treatment deci-
sions [21-23]. Once a patient has made the decision to
start treatment, the integration of dual or triple therapy
into daily life and the management of symptoms become
central self-management tasks with major impacts on
health outcomes. For example, medication adherence de-
fined by the World Health Organization (WHO) as “the
extent to which a person’s behaviour – taking medication,
following a diet, and/or executing lifestyle changes–corre-
sponds with agreed recommendations from a health care
provider” [24] during dual therapy is often insufficient,
even though non-adherence has been linked to insufficient
virological response [25,26]. Studies have revealed that
achieving an SVR via triple therapy is likewise adherence-
dependent, i.e., 80% of BOC doses must be taken over the
assigned treatment period [27]. However, a study of dual
therapy showed e.g. 100% adherence in 38% of patients
over the full initially intended treatment period [26].
Side effects are additional challenges and have been
shown to negatively impact treatment adherence [28,29].
Preliminary evidence has also indicated that interventions
improve HCV patients’ adherence and thus increase the
possibility of SVR [30-32]. However, to date, it is unclear
which intervention content, structure or application is
most effective. Across several chronic conditions such as
HIV, arthritis and diabetes, an understanding of the
patients’ illnesses and treatment experiences has strength-
ened the development of effective self-management inter-
ventions [33,34].
So far, though, little is known about how patients im-
plement triple therapy in their everyday lives and how
they deal with side effects [35]. To enable the develop-
ment of effective intervention programs, this study ad-
dresses the question of how HCV patients experience
the everyday dealing with protease-inhibitor-based triple
therapy and what support they need. As the generation
of DAAs for all genotypes, including recently-introduced
interferon-free regimes, are expected to have less severe
side effects, and many HCV patients require treatment, this
knowledge can improve treatment support tremendously.
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However, depending on the regimen, IFN and RBV are still
recommend by the European Association for the Study of
the Liver (EASL) and are always appropriate [36].
Methods
A qualitative research approach was selected for the de-
scription of patients’ triple therapy experiences. This is ap-
propriate when prior knowledge and empirical evidence
are limited and understanding of patients’ perspectives is
needed to develop culturally sensitive instruments and ef-
fective interventions [37]. Methodologically, the thematic
analysis used for this inquiry is aligned with a constructivist
orientation [38]. Based on this approach, we assume that
individuals construct their own realities and meanings
from their culturally available language and subjective ex-
perience to make sense of their daily lives. Meaning is
understood as generated and co-created in researchers’ in-
teractions with the data [39]. More concretely, we theoretically
oriented the inductive identification of thematic patterns
(themes) to reflect commonalities and differences
in patients' experiences to produce clinically relevant
knowledge [40].
Study site/study group
The study was performed between October 2012 and
February 2013 in three outpatient clinics: an infectious dis-
ease clinic and a gastroenterological/hepatological clinic,
both at the same hospital, and a clinic for internal medi-
cine and infectious diseases at a center for addiction medi-
cine. This multicenter approach was chosen because few
patients were being treated with triple therapy at the time
of investigation. The aim was to recruit 10 – 15 patients–
a number usually sufficient to provide meaningful insights
into patient experiences through the identification of
themes reflecting commonalities and differences. Inclu-
sion criteria were: being 18 years of age or older, having
four weeks or more experience with a protease-inhibitor-
based HCV therapy (ongoing, completed or discontinued),
being in outpatient medical care and having the ability to
participate in an interview in German. Persons whose
treating physicians judged the additional burden of study
participation unacceptable in relation to their emotional
state (e.g., pronounced depressive symptoms, suicidal
ideation) were excluded. Recruitment used maximum
variation sampling [41]. The principle of this sampling
strategy is to interview as diverse a selection of people as
possible. In a relatively small sample, as is usual in qualita-
tive studies, this maximum variation sampling allows the
integration of a broad range of experiences into data ana-
lysis. Considering that limited sampling information was
available from clinical experience and literature, we sought
to include subjects who, according to their characteristics
and circumstances, would add different experiences to
the analysis. To obtain the maximum variation sample
we assured that participants differed according to gender,
age group, route of HCV infection and PI in their treat-
ment regimen (TPV or BOC). An additional effort was
made to include persons with HIV/HCV-Coinfection and
intravenous drug users (IDUs). As many members of this
patient group need treatment but are known to face
multiple additional medical and social challenges, it was
deemed important to include their experiences [42].
Patients were informed about the study either during a
medical check-up visit or by telephone by a healthcare
provider whom they knew. Of the 15 persons contacted
about the study, 13 agreed to participate. Of the reasons
for refusal, one patient's travel plans conflicted with the
study timetable and the other did not wish to spend the
necessary time participating.
Data collection
Data collection was performed via open-ended inter-
views. Prior to the study, guidelines were developed with
open questions on experiences concerning illness, treat-
ment, symptoms and interactions with significant others,
including healthcare providers. For all participants the
interview started with the following open question:
“Would you please tell me about your day-to-day experi-
ence with hepatitis C treatment?” Based on the patient’s
narratives, mentioned topics were explored in depth. The
interviewer asked about any topics listed in the interview
guide but not brought up by patients. Data analysis was
started after the first three interviews.
Throughout the study, we continuously integrated and
discussed themes from preliminary analysis to identify
commonalities and differences between participants. Fol-
lowing Thorne's position that being able to explore all
possible theoretical aspects of a phenomenon is useful in
the discovery of basic social processes, but is less logical in
documenting human health experience (where the focus
is on cases' differences and commonalities) [40], we did
not aim for theoretical data saturation.
The first author (MR), an experienced addiction medi-
cine and infectious diseases nurse and Master’s student,
conducted the interviews. She was supervised by the last
author (DN), an experienced qualitative researcher. She
did not provide nursing care for any of the participants.
The participants decided on the locations for their inter-
views. Four were conducted at home and nine in the
hospital after a medical consultation. At one interview
a 2-year-old child was present; at another the patient’s
partner attended to fill in the gaps in her partner’s mem-
ory during a life-threatening episode. Otherwise, only the
interviewer and the participant were present. The inter-
views lasted 30–64 minutes (mean: 45 minutes), and were
recorded and transcribed verbatim, omitting the patient’s
or any other names, as well as the place of interview.
Transcripts were not returned to patients for comment.
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After the open-ended interviews, sociodemographic
and medical data were collected using a structured ques-
tionnaire (date of birth, gender, first diagnosed, former
dual therapy experience, triple therapy status (e.g., on-
going, completed or discontinued), PI used, residence
situation, occupation, ability to work). Field notes were
also made after each interview.
Data analysis
The transcripts were systematically analyzed according
to the thematic analysis method described by Braun and
Clarke [38]. This procedure enabled the researchers to
identify significant recurring topics, interpret them and set
them in relation to one another in a constituent pattern.
Along with the analytic steps, which followed Braun and
Clarke [38], shown in an additional file (see Additional
file 1: Table S1), the role of each author in this process is
presented in Table 1. The software program ATLAS.ti 7.0
(Scientific Software Development GmbH Berlin) was used
to support data analysis. Following the checklist for good
qualitative analysis (see Additional file 2: Table S2), each
step of the analysis was discussed with researchers and
HCV care experts who had not been directly involved in
development of the themes used.
After data analysis was finalized, results were trans-
lated into English by a professional translator. The trans-
lation was checked and adapted by the research team.
Very specific difficult-to-translate wordings were added
in parentheses in the language of origin.
The 15-item criteria checklist developed by Braun und
Clarke [38] was used to guarantee the quality of data.
An additional file shows this checklist (see Additional
file 2: Table S2). All participants were provided detailed
verbal and written information about the study, and all
signed written informed consent forms. The study was
approved by both relevant bodies of the Swiss Association
of Ethics Committees for clinical trials in St.Gallen (EKSG,
reference number 12/122 L/1B) and Zürich (KEK-ZH, ref-
erence number 2012–0484). To ensure an accurate and
transparent manuscript reporting it adheres to RATS
guidelines.
Results
Of the eight men and five women who participated in the
study (aged 36–63 years), eight were living with partners
or family, three alone and two in an institution. Their
HCV diagnoses had been made 1.5 – 28 years previously.
Before starting triple therapy, twelve of thirteen patients
had experienced fibrosis stages that indicated treatment.
Eight had prior experience with dual therapy and five had
none. For their triple therapy, the PI Telaprevir had been
administered to nine persons and Boceprevir to four.
Demographic and medical data are presented in Table 2.
Participants' stories revealed that before starting triple
therapy, all believed that, because of the condition of
their liver, the recommended treatment was necessary to
improve or maintain their health long-term. Perceiving
no alternatives, but considering the new triple therapy a
“real chance” to overcome the disease, they had chosen
to undergo therapy. This decision was strengthened by
the knowledge that treatment time would be limited.
Prior to the treatment trial's commencement, all had
rated it as worth a try. One woman, for example, com-
pared the trial to her HIV therapy:
I also think it’s good that it only lasts a year and not
like in HIV. For that, you have to take it forever. I’ll
push it through for a year, even if it’s not pleasant, as
long as it does some good. If it doesn’t do any good,
then it’s logical that I wouldn’t. (P10, 52 yrs)
Table 1 Six phases of thematic analysis by Braun & Clarke [38] and role of authors
1. Familiarising yourself
with your data
The accuracy of the transcribed interviews was checked. Transcripts were read by three authors (MR PK DN) and notes
of initial ideas were made and discussed in the research team.
2. Generating initial codes All transcripts were coded systematically using inductive methods. The first five interviews were coded by three authors
(MR PK DN) and codes were discussed until consensus was reached. The following eight transcripts were coded by the
first author (MR), codes and quotes were presented and discussed with PK DN. With the support of Atlas.ti codes
remained associated with the transcripts (quotes).
3. Searching for themes Based on the code lists the research team (MR PK DN) summarized several codes into meaningful themes whose
relevance emerged across several interviews. A preliminary description of the main and subthemes was made.
4. Reviewing themes The first author (MR) checked the preliminary description of themes with the original data (transcripts). Inconsistencies
were discussed in the research group. The first author undertook adjustments and defined the main theme and
subthemes. The last author (DN) who has expertise in thematic analysis reviewed these themes and together with the
first author related themes to a thematic map.
5. Defining and naming
themes
The first author (MR) returned to the transcripts and worked out the specific thematic content, then, with DN, worked
out the overall story line. The preliminary results were presented to authors and experts in care of HCV patients.
According to this discussion some refinements were made.
6. Producing the report The first author (MR) wrote a first draft of the scientific report, and selected vivid quotes to illustrate themes. The last
author (DN) reviewed the report and necessary adjustments were made. The report was submitted to the research
team for critical assessment, and the team's responses were recorded.
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Despite their high initial levels of motivation, all
test patients later found themselves struggling to con-
tinue with the therapy, which was physically, emo-
tionally and socially draining, and which dominated
their everyday lives. The constitutive theme character-
izing this experience is “Fighting an uphill battle”.
This common experience was fostered by a process de-
scribed by three sub-themes: “encountering surprises”,
“dealing with disruption” and “reaching the limits of sys-
tems” (see Figure 1).
Fighting an uphill battle
All patients remembered the treatment period as a huge
physical and emotional burden that disrupted their
everyday life and pushed them to the limits of their en-
durance. One man described his experience as follows:
It’s a quite hard therapy and required a lot of strength.
I feel literally how it tears me in all directions. There
are phases in which it is easier, but a general feeling is
always present. There are up- and downturns inside
me like on a roller coaster and sometimes I say it is
enough, I cannot stand it any longer, life is too
exhausting. (P12, 55 yrs)
During this trying time, patients were additionally con-
fronted with the limits of the support available from
healthcare professionals, family and friends. Amplified by
health-threatening and even life-threatening experiences,
patients described everyday life as defined by existential
battles against innumerable side effects, which started for
some immediately and for others later in the course of
treatment. In analogy to their experience they used a battle
language. For example, patients described that they fought
against symptoms or experienced “hell-fire”. In addition
to physical and emotional burdens, patients experienced
social limitations, even to the point of isolation. One
woman (P7, 52 yrs) said she felt half dead during
therapy – a “zombie” with no influence on anything and
Table 2 Patients characteristics
Variable Patients (n = 13)
HCV Genotype 1 13 (100%)
Fibrosis stage 0-1 1 (8%)
Fibrosis stage 2 3 (23%)
Fibrosis stage 3 3 (23%)
Fibrosis stage 4 6 (46%)
Gender Male 8 (62%)
Female 5 (38%)
Mean age in years (range) 49 (36–63)
Transmission IDU1 6 (46%)
Blood products 2 (15%)
Unsafe sex 1 (8%)
Unsafe tattooing 1 (8%)
Unknown 3 (23%)
Opioid substitution 3 (23%)
Multimorbidity2 4 (30%)
First diagnosed mean
years (range)
12.5 (1.5 - 28)
Treatment experience Naive 5 (38%)
Dual therapy 1× 7 (54%)
Dual therapy 2× 1 (8%)
Protease inhibitor Telaprevir 9 (70%)
Boceprevir 4 (30%)
Status proteaseinhibitor
therapy
Ongoing 5 (38%)
Completed 5 (38%)
Discontinued3 3 (23%)
Residence situation With Partner/
Family
8 (62%)
alone 3 (23%)
Institution4 2 (15%)
Occupation before triple therapy 10 (80%)
Job related working ability
during triple therapy
0-25% 5 (50%)
26-50% 1 (10%)
51-75% 1 (10%)
76-100% 3 (30%)
1Intravenous drug user.
2One patient with HIV, haemophilia, Depression or Schizophrenia.
3Two patients due to neutropenia, one patient due to unbearable side effects.
4Mental hospital, assisted accommodation.
Figure 1 Constitutive theme and sub-themes. The constitutive
theme “Fighting an uphill battle” fostered by a process of three
sub-themes: “encountering surprises”, “dealing with disruption” and
“reaching the limits of systems”.
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no idea what was happening to her. The symptoms affected
many very strongly. For example, they “hit rock bottom”,
were “broken on the wheel”, “run over by a truck”, “put
through the mill”, or “forced to crawl on all fours”. And the
effects could come on very quickly: one had to be admitted
to an emergency room “out of the blue”. Those who suf-
fered the most pronounced symptoms agreed that simply
maintaining one's course demanded tremendous strength
and discipline. Against this stream of suffering, only the
hope of a cure drove them onward. One man said:
And then I battled the rash and told myself that I
would carry on, heaven knows how, but I simply would
not fail. (P3, 39 yrs)
The ever-present feeling of “fighting an uphill battle”
which beset the patients was amplified by the fact that,
despite the information they had received, their symp-
toms surpassed their imagination.
“Encountering surprises”
The patients reported that prior to the beginning of ther-
apy, HCV healthcare providers had informed them of side
effects they might perceive to varying degrees. Therefore,
all expected unpleasant and undesirable symptoms. Based
on experience with other medications, including dual
therapy, some expected similar symptoms, while others
expected greater difficulties from the start. For most, how-
ever, the symptoms surpassed all expectations and were
unexpected despite preparation. One woman described
this as follows:
Actually, I worked the whole time during the first therapy,
yet I can’t remember exactly, but it was never, ever in the
way, never to the extent [of the triple therapy side effects],
not the icy cold and the drying out, not all that hair loss,
either. That’s why I was shocked. (P1, 60 yrs)
Often the patients lacked the specific vocabulary to de-
note their symptoms, reporting that they would be diffi-
cult to explain to anyone who had never experienced
them. Instead, they used vivid descriptions, such as “freez-
ing torpor”, ”frozen skeleton”, “looking like a spotty mon-
ster”, “moving like a robot”, wanting to “get the carving
knife and scrape that stuff off”, “having the feeling of con-
sisting only of tablets”. Their healthcare providers seemed
not to have sufficient experience with other patients to
help with finding language. For several participants
the symptoms were often so numerous that the bur-
den of suffering could barely be borne. One man de-
scribed it as follows:
Life at the moment is only the fight against side effects.
Hardly over the worst of one, and up comes the next
already. There were maybe four or five most difficult
things which were really stressful, and then there were
another 20, 30 minor things, like mental problems,
difficulties going out among people, suddenly being
easily frightened and uncertain. I’m not otherwise a
person who lacks self-confidence. Yes, there are a lot of
such things. (P2, 39 yrs)
Even patients with fewer side effects said many of them
were agonizing. Also, because symptoms often arose with
great speed and force, and the patients lacked any related
experiences, they had few strategies for dealing with them.
One woman said:
The side effects were very severe, in particular
depression was heavy. What was worst was that it
started right away, that everywhere there is mucosa
hurt, everything was inflamed. Like the nose, mouth,
vaginal area, everywhere. And I also got hemorrhoids
right away, within three weeks, and that was brutal
pain, I didn‘t know how to deal with it. (P7, 52 yrs)
The onset of side effects was usually unpredictable.
Several might occur suddenly and without warning, or
they might develop gradually; so it was impossible to
know what condition one would be in even two hours in
the future. One man (P5, 48 yrs) said that “in addition to
the work, it was quite hard, since there was no central
thread and one couldn’t say how one would feel; there
was no rhythm”.
The symptoms led to decisive changes in the patients’
lives, against which they struggled. Their daily lives
changed totally.
“Dealing with disruption”
The patients reported that, since starting therapy, nothing
was the same as before. Mind and body, and emotional life
no longer functioned as usual and considerably reduced
the quality of life. One man described the effect as follows:
Absolutely nothing is the same as it was, neither
sleeping nor feeling, simply mind or body, it’s not the
same any more, no; even when I touch myself, the
whole feeling is simply different; smelling oneself
changed; there’s a disgusting taste in the mouth and
food tastes different. Nothing, really nothing is the
same anymore. (P2, 39 yrs)
One serious problem for the patients was their lack of
productivity, which was usually attributed to great fatigue
and accompanied by an absolute lack of energy and
strength. They were unable to satisfactorily perform every-
day tasks at home, at work, as partners or as parents,
which could result in further difficulties. One woman
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(P7, 52 yrs) said she “could no longer lead a normal life
and only slept after work”. In addition, for example, one
was “no longer able to open a bottle, concentrate for any
length of time at work, or stand the lively children and
not react with hostility”. What strength remained was
often focused on existential priorities such as one's em-
ployment or essential everyday tasks; others were pushed
back. A man reported:
And as for my wife, she doesn’t get what she would
like. I can’t give her what I don’t have at the
moment. That also has to do with potency, there’s
such a loss of strength, loss of desire, it’s really
terrible for our relationship because I have no
strength. And sexuality is one area in which
strength plays an important role, and if it’s not
there, there’s frustration. (P12, 55 yrs)
Prior to therapy, most participants' HCV infections
had produced no readily apparent symptoms. Consider-
ing their therapy a very personal matter, they discussed
it with few others, and hoped to prevent the side effects
from becoming obvious. However, these were virtually
impossible to conceal, and many were ashamed of their
condition and appearance. To protect themselves and
their families from gossip and isolation, most carefully se-
lected to whom and how fully they revealed the details of
their HCV infection. Otherwise, they developed strategies
to avoid disclosure. For example, many withdrew from
their social environments during the therapy period, lead-
ing some to feel very isolated. One man described this
as follows:
I hid it for one reason because I really didn’t know
how people would react. In my environment, it’s a
touchy subject and people are talking about who has
the disease and why. Another main reason is my ego, I
don’t want somebody to judge me as sick. It would be
enough to see just one glance from someone that tells
me, you think I’m sick. If I’m sick, then I’m sick, I’m
absolutely not ashamed of it, but it is doubtlessly a
peculiar situation, in which [as long as] I don’t admit
that there’s something wrong, there’s nothing wrong.
Moreover, if anyone points at me and says "sick", it
would be awful. There are, of course, people I could
tell this to, surely, but in the background I always
think some day he will tell it to another person, that’s
why I just keep my mouth closed; I simply didn’t want
anyone to know. (P3, 39 yrs)
The changes which were experienced as decisive were
often hard for the patients to bear and they needed a lot
of strength and willpower to battle on. This also brought
them to the limits of their resilience.
“Reaching the limits of systems”
Initially the patients were confident that they could
complete their therapy regardless of the difficulty. How-
ever, the changes they recalled as most decisive pushed
them to the limits of their strength, willpower and resili-
ence. Struggling with symptoms, they described losing
their feeling of self, which left them unable to assess
themselves appropriately. This sometimes led to danger-
ous situations, in which they felt very dizzy or even col-
lapsed. Some recalled how limited their judgments and
actions became, or how they feared losing control be-
cause of depression or aggression. One man explained:
There were situations in which I felt so awful that I
almost wanted nothing so much as to be admitted to
hospital,…at the end of my rope, emotionally and
physically. I know when I’m sick, that usually it will
pass, and I don’t see the doctor. But this time the limit
was overstepped where I am no longer able to judge,
and that was a certain danger, since I live alone.
There were situations in which…I would have best
liked to be in hospital [outpatient clinic] that I was
judged by someone else. (P2, 39 yrs)
Most patients regarded their HCV healthcare pro-
viders as valuable sources of support regarding unpre-
dictable symptoms. Offering short-notice appointments
via telephone, text message or email, these low-profile,
reliably accessible clinicians were extremely helpful to
evaluate symptoms or problems with treatment regimens.
Concerning symptom control, though, while patients
understood that the newness of the protease-inhibitor-
based triple therapy made full management impossible,
they were surprised at how limited the clinicians' know-
ledge was. Nevertheless, they appreciated clinicians who
empathized with them and assisted in any way in their
battle against side effects. This gave them a feeling of sup-
port and partnership in seeing their therapy through:
I had the feeling that even for my nurse and doc this
was not routine. Then I realized they were fighting
along with me. I really absolutely knew: I suffer from
something they don’t really know about. But let’s
say, at the worst point, both of them stood with me.
(P3, 39 yrs)
Patients expected healthcare providers to accurately
evaluate their health status and take the lead when they
themselves were too impaired to assess or react appropri-
ately to a crisis. One woman (P4, 63 yrs) recalled being
unaware that she was approaching the point of collapse,
and emphasized that, though she understood her clini-
cians' lack of specific experience, it would have been help-
ful if one had intervened and sent her to hospital earlier.
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Many participants recounted how their inability to de-
scribe their symptoms had sometimes prevented them
from informing their care teams either promptly or
clearly. Also, due to their high number of symptoms, they
usually mentioned only those that caused the most stress.
Further, they were unaccustomed to reporting symptoms
emphatically enough for them to be noted. In retrospect,
patients rated open communication with clinicians, in-
cluding discussions of even the slightest change during
therapy, as essential. One noted that the care personnel
could not be expected to be “clairvoyant”.
Patients had tremendous faith in their clinicians' ad-
vice. Despite information about side effects, and even in
difficult situations, many followed therapy instructions
precisely and without question. One man reported:
I simply took the medication without question and
thought, you’ve got to take this every eight hours; but I
didn’t think anything bad, I simply took it without
question. The doctor said I must take it this way. At
the end it was difficult, but I didn’t know who was to
blame, then, when I suddenly had attacks of shivering.
I never would have thought it was because of the
medication, someone should have told me more
clearly. (P9, 61 yrs)
Beyond their clinical care, several patients explained
that, considering their often very poor physical and emo-
tional condition, they genuinely needed and received ex-
tensive support in everyday tasks, and said support from
partners, family and friends helped them endure the
therapy. These people helped with such tasks as house-
work or organizing and keeping appointments, and even
occasionally supplied motivational talks or instructions for
action. This level of assistance usually entailed a great
challenge for the supporting person, and required close
cooperation with health care providers. Conversely, living
alone without support during the therapy period was
unanimously rated as problematic. One man (P6, 40 yrs)
said “I would have missed all my appointments because of
drowsiness if my father hadn’t helped me with the ap-
pointments and driven me there”.
The majority of patients found medication management
difficult and time-consuming. However, even though their
regimens required injections, timely intake of medications
three times a day and food restrictions, none mentioned
this explicitly until asked. Once the topic had been intro-
duced, though, all acknowledged the importance of taking
medications exactly on time. They also described phases
during which taking medication was easier and others
when they had to force themselves to overcome feelings
of aversion. Nonetheless, despite the difficulties, to maximize
their chances of attaining a cure, they summoned the
necessary discipline, and eventually taking medication
became routine. Of the entire participant group, only
two men, both formerly IDUs from substance abuse treat-
ment clinics, reported that they couldn’t take the medica-
tion three times daily as prescribed by the doctor because
they were too drowsy and couldn’t wake up on time. Their
IFN injections were administered to them weekly by a
nurse, which both rated positively. One was able to reduce
his medication intake to twice daily after consultation with
his health care providers, enabling regular administration
from then on. The other terminated PI intake due to un-
bearable side effects and continued with dual therapy.
In summary, all patients considered the triple therapy
an enormous physical and emotional battle: perseverance
demanded all of their willpower and discipline. Their mo-
tivation was the possibility of cure and adherence with
their medication regimen was not a foremost topic, in
spite of the radical changes and burdens brought on by
the many side effects. These were often unexpected and
difficult to discuss or manage. As a result, patients oper-
ated at the very limits of their endurance, and all collabo-
ration between HCPs and patients was exploratory, i.e., as
PI therapy was extremely new, the clinicians' experience
was severely limited and related literature remained scant.
Still, regardless of their potential therapeutic success, all of
the patients were confident of the value of their decision
to undergo therapy.
Discussion
This thematic analysis provides insights into HCV pa-
tients' experiences with PI based triple therapy. Before
beginning their therapy, these patients were powerfully
motivated to improve their health and achieve a cure.
For dual therapy, patients have associated concerns re-
garding disease progression, loss of liver function and
other potential health problems with treatment initiation
[43,44]. However, this study group's homogeneously high
motivation might not reflect the attitude of the majority
of HCV patients in need for treatment. Studies have
shown that large proportions of patients (10% - 44%)
undergoing dual therapies typically discontinue treat-
ment [15,43,45]. Although we included participants from
three different outpatient clinics and used maximum vari-
ation sampling to ensure diverse characteristics and living
circumstances, there might have been an earlier clinical
selection of highly motivated patients treated with the
then-newly-available triple therapies and the next generation
of interferon-free treatments.
Soon after starting triple therapy, our highly-motivated
study group found themselves struggling. The constitutive
theme–“Fighting an uphill battle”–describes the patients'
common existential experience of coping with the thera-
py's side effects and indirect negative consequences. Bell
et al. describe similar existential treatment experiences
among cancer patients receiving adjuvant chemotherapy
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[46]. However, in contrast to cancer patients, who saw
their symptoms as a means of tracking treatment effect-
iveness and increasing the possibility of remission, this
study's HCV patients indicated beliefs congruent with re-
search on triple therapy, i.e., that it numerous side effects,
including possible life threatening adverse events, are to
be expected, but that no associations exist between symp-
toms and success [18,47].
In this study, despite information from healthcare pro-
viders and research oriented treatment reports, the symp-
toms experienced surpassed the patients' expectations
(as described in the “Encountering surprises” subtheme).
Across chronic conditions, high symptom numbers, high
symptom distress and low perceived symptom manage-
ability have negative impacts on health outcomes includ-
ing quality of life and medication adherence [48,49]. Given
the high number of HCV patients who commonly inter-
rupt dual therapy and the high symptom burden of triple
therapy, it can be hypothesized that mitigating patient dis-
tress via early symptom management support will increase
successful completion of therapy and would decrease
dropout rates in less persistent patient groups. And while
even healthcare providers were occasionally surprised by
the severity and diversity of the new treatment's side ef-
fects, the first step of effective symptom management is to
assess patients' perceptions of their symptoms [50]. How-
ever, our records illustrate very clearly that the partici-
pants' symptom experiences were often so foreign to them
that only metaphoric language was sufficient to explain
them. Therefore, standard biomedical symptom assess-
ment by health care providers might not be sufficient to
capture the details of symptoms or symptom clusters that
impact safety, adherence and treatment persistence. And
with the prospect of HCV treatment options appearing in
the near future, a proactive and patient-oriented system of
symptom assessment will remain an important compo-
nent of clinical HCV management. On the one hand these
treatments are expected to entail fewer and less se-
vere adverse events; on the other, they will also be used in
patients in advanced stages of the disease, suffering co-
morbidities and living in more complex circumstances.
As described above in the subtheme “Reaching the limits
of systems” the therapy's drastic physical and emotional
effects fundamentally disrupted participants’ everyday
lives and severely limited their social interactions. Similar
phenomena have been described for symptomatic but un-
treated HCV patients, as well as for other chronic condi-
tions [51].
However, the radical social changes described by our
study participants appeared heavily influenced by their
fear of stigmatization. In order to protect themselves from
negative social consequences, it is common for patients
with stigmatized infectious diseases such as HIV and HCV
to make careful disclosure decisions and in some cases
conceal their conditions as fully as possible [52-54]. Our
illness-experienced study group described a range of
selective disclosure management strategies that had ap-
parently been effective before the start of their triple ther-
apy. During treatment, though, the sudden appearance of
visible symptoms led to isolation when support was most
needed. In some cases, though, the perception of societal
rejection might simply have been internalized, i.e., the fear
of stigmatization may have led some to project it onto
those around them. Recent evidence shows promising
approaches to combatting internalized stigma (self-
stigmatization) by improving both self-esteem and help-
seeking behavior [55,56]. To minimize stress and improve
social support during HCV treatment, healthcare pro-
viders should discuss stigmatization fears and disclosure
management strategies during consultations both before
and during treatment.
The importance of social support is also apparent in the
“Reaching the limits of systems” subtheme. Participants
recalled both how their symptoms sometimes impaired
their judgment and how, during these periods of diminished
capacity, the support of family members and close friends
was crucial. The positive effects of social support on
chronically ill patients' health outcomes is well docu-
mented. For example, for patients living with HIV and re-
ceiving antiretroviral treatment, a stable partnership is
associated with a slower progression to AIDS or death
[57]; and among patients living with HCV, those who are
married are more likely to complete dual therapy [43]. In
addition to companionship, close social contact is known
to have multifaceted benefits, including emotional, instru-
mental, informational support [34,58,59].
Since study patients revealed problems with judgment
and efficacy concerning sometimes life threatening symp-
toms, a sound knowledge of HCV treatment and decision
making skills is important not only for patients but for
their close support persons. This requires healthcare pro-
viders to identify close support persons and integrate
them into patient education programs. Where social con-
tact with support persons is limited, professional support,
e.g., community care, should be intensified.
Based on current evidence and clinical expertise, diffi-
culties in adherence with the complex triple therapy reg-
imens are to be expected [18,28,59]. Surprisingly, this
study's patients did not raise the issue of medication
management. However, as some patients mentioned dif-
ficulties when asked, adherence issues may simply have
been eclipsed by the intensity of the medications' side ef-
fects. Given that heavy symptom burdens (often much
lighter than those described by this study's patients) are
known to impact adherence, and that poor adherence to
dual therapy is known to impact virological response
[25-27], it is important to integrate non-judgmental ad-
herence assessment into routine clinical care.
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The insights provided by this study illustrate the need
to assess patient perspectives of new treatment options
in ‘real-life’ settings–as opposed to those of clinical trials.
In clinical care, clinicians routinely treat patients who
would have been excluded from clinical trials due to
medical, social or behavioral problems. Research shows
that exactly such medical or socio-behavioral challenges
impair results in patients with HCV [42,60,61]. There-
fore, despite the availability of new HCV treatment op-
tions, it remains important to assess patients’ treatment
experiences with various other regimens where, based
on information from clinical trials, these treatments
offer higher tolerability and manageability. Further-
more, considering the extremely high cost of the currently-
available IFN-free regimes with improved tolerability,
it can be expected that they will not be used in all
countries.
Limitations
The study was limited in two ways: a) its selective re-
cruitment and b) its single-point-in-time interviews. Re-
cruitment was influenced by the fact that participants
would be among the first in Switzerland to be treated
with the then-newly available protease inhibitors and
were therefore both unusually motivated and closely
monitored. Single-point-in-time interviews might not
have shown individual processes in the treatment experi-
ence as well as serial interviews over the course of treat-
ment. However, while the study's qualitative design may
limited the results' applicability to other groups of HCV
patients, it allowed deep insights into topics such as
the participants' inability to describe their symptoms,
which could not have been investigated using quanti-
tative assessments.
Conclusions
For patients undergoing HCV triple therapy, the burden is
extreme, but can be lightened by early and continuous
support with the negative effects of social stigma and self-
stigmatization. During treatment, social support can be
strengthened by the integration of close support persons
into patient education. An important goal of this process
is to build and strengthen collaborative relationships be-
tween patients, support persons, and healthcare providers
concerning clinical decision-making. In this respect, wher-
ever possible, health providers should eliminate access
barriers and use patient-centered communication styles to
assess and support symptom management and medication
adherence. With the introduction of DAAs to ‘real-life’
settings, high accessibility and patient-centered symptom
and adherence assessment will demand multidisciplinary
team approaches that integrate input from both the pa-
tients and their close support persons [53,55,56].
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